Recombinant Human Dermatopontin Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 4629-DP
Key Product Details
Product Specifications
Source
Mouse myeloma cell line, NS0-derived human Dermatopontin protein
Gln19-Val201, with a C-terminal 6-His tag
Gln19-Val201, with a C-terminal 6-His tag
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
No results obtained: Gln19 predicted
Predicted Molecular Mass
22.8 kDa
SDS-PAGE
23 kDa, reducing conditions
Activity
Measured by its ability to modulate collagen fibrillogenesis.
20 µg/mL of rhDermatopontin can significantly enhance the rate collagen fibrillogenesis.
20 µg/mL of rhDermatopontin can significantly enhance the rate collagen fibrillogenesis.
Formulation, Preparation and Storage
4629-DP
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
Reconstitute at 100 μg/mL in sterile PBS.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Dermatopontin
Dermatopontin, also known as TRAMP (tyrosine rich acidic matrix protein), is a widely expressed noncollagenous protein component of the extracellular matrix (1, 2). Mature human Dermatopontin shares 96%, 92%, and 92% amino acid sequence identity with bovine, mouse, and rat Dermatopontin, respectively. It is a 22 kDa molecule that is tyrosine sulfated but not glycosylated (3, 4). Dermatopontin contains three disulfide bonded loop structures that enclose conserved hexapeptide motifs (5). It accelerates collagen fibril formation in vitro, and Dermatopontin deficient mice exhibit altered collagen matrix deposition and organization (6-8). Dermatopontin is down-regulated in fibrotic growths such as leiomyoma and scar tissue (9, 10). It binds both TGF-beta and the proteoglycan decorin, interactions that can increase the bioavailability of TGF-beta (11, 12). Dermatopontin promotes bone mineralization under the control of the vitamin D receptor and inhibits BMP-2 effects on osteoblast precursors (13, 14).
References
- Okamoto, O. and S. Fujiwara (2006) Connect. Tissue Res. 47:177.
- Superti-Furga, A. et al. (1993) Genomics 17:463.
- Forbes, E.G. et al. (1994) FEBS Lett. 351:433.
- Cronshaw, A.D. et al. (1993) Matrix 13:255.
- Neame, P.J. et al. (1989) J. Biol. Chem. 264:5474.
- MacBeath, J.R.E. et al. (1993) J. Biol. Chem. 268:19826.
- Takeda, U. et al. (2002) J. Invest. Dermatol. 119:678.
- Cooper, L.J. et al. (2006) Invest. Opthalmol. Vis. Sci. 47:3303.
- Catherino, W.H. et al. (2004) Genes Chromosomes Cancer 40:204.
- Kuroda, K. et al. (1999) J. Invest. Dermatol. 112:706.
- Okamoto, O. et al. (1996) J. Biochem. 119:106.
- Okamoto, O. et al. (1999) Biochem. J. 337:537.
- Pochampally, R.R. et al. (2007) J. Bone Miner. Res. 22:1338.
- Behnam, K. et al. (2006) Connect. Tissue Res. 47:271.
Alternate Names
DPT, Eq1
Gene Symbol
DPT
UniProt
Additional Dermatopontin Products
Product Documents for Recombinant Human Dermatopontin Protein, CF
Product Specific Notices for Recombinant Human Dermatopontin Protein, CF
For research use only
Loading...
Loading...
Loading...